Insider Selling: Foamix Pharmaceuticals Ltd (FOMX) Insider Sells $33,400.00 in Stock

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) insider Meir Eini sold 5,000 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $6.68, for a total transaction of $33,400.00. Following the sale, the insider now directly owns 16,271 shares in the company, valued at $108,690.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Meir Eini also recently made the following trade(s):

  • On Wednesday, January 10th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.05, for a total transaction of $30,250.00.
  • On Monday, January 8th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.17, for a total transaction of $30,850.00.
  • On Tuesday, January 2nd, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.18, for a total transaction of $30,900.00.

Shares of Foamix Pharmaceuticals Ltd (FOMX) traded up $0.01 during trading on Friday, hitting $6.41. 58,087 shares of the stock were exchanged, compared to its average volume of 92,639. Foamix Pharmaceuticals Ltd has a 52-week low of $4.03 and a 52-week high of $11.11. The stock has a market capitalization of $239.95, a P/E ratio of -3.98 and a beta of 1.62.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative return on equity of 54.81% and a negative net margin of 1,439.32%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.90 million. During the same period in the previous year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was down 64.6% compared to the same quarter last year. analysts expect that Foamix Pharmaceuticals Ltd will post -1.35 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. DAFNA Capital Management LLC lifted its holdings in shares of Foamix Pharmaceuticals by 9.2% in the second quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after buying an additional 30,000 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Foamix Pharmaceuticals by 38.6% in the second quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Foamix Pharmaceuticals in the second quarter worth about $304,000. UBS Asset Management Americas Inc. lifted its holdings in shares of Foamix Pharmaceuticals by 1.6% in the second quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Foamix Pharmaceuticals by 1,738.5% in the third quarter. Wells Fargo & Company MN now owns 47,801 shares of the specialty pharmaceutical company’s stock worth $265,000 after buying an additional 45,201 shares in the last quarter. 57.43% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have commented on the stock. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 5th. Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, Guggenheim reaffirmed a “buy” rating and set a $8.00 price objective on shares of Foamix Pharmaceuticals in a report on Thursday, December 14th.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/21/insider-selling-foamix-pharmaceuticals-ltd-fomx-insider-sells-33400-00-in-stock.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply